This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

THIS PAGE BLANK (USPTO)



WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7: A61L 27/58, 27/42, 27/46, 31/14, 31/12 (11) International Publication Number:

WO 00/47245

(43) International Publication Date:

17 August 2000 (17.08.00)

(21) International Application Number:

PCT/GB00/00475

A1

(22) International Filing Date:

11 February 2000 (11.02.00)

(30) Priority Data:

9902976.1

11 February 1999 (11.02.99)

GB

(71) Applicant (for all designated States except US): GILTECH LIMITED [GB/GB]; 9/12 North Harbour Estate, Ayr KA8

8BN (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HEALY, David, Michael [IE/GB]; Midton House, By Alloway, Ayr KA7 4EG (GB). GILCHRIST, Thomas [GB/GB]; The Lodge, 67 Midton Road, Ayr KA7 2TW (GB).

(74) Agent: MURGITROYD & COMPANY; 373 Scotland Street, Glasgow G5 8QA (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: BIODEGRADABLE COMPOSITE MATERIAL FOR TISSUE REPAIR

(57) Abstract

There is described a biodegradable composite material for tissue repair comprising a water-soluble glass, preferably as glass fibres and/or particles in the form of a matrix, impregnated with a biodegradable polymer. An especially preferred polymer is poly ε-caprolactone. The biodegradable composite is particularly useful for the repair of nerve and/or bone tissue, especially the bones of the skull. A method of producing the composite material is also described.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AL	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AM AT	Amenia	FR	France	LU	Luxembourg	SN	Senegal
	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AU	Australia Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
AZ	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BA		GH	Ghana	MG	Madagascar	TJ	Tajikistan
BB	Barbados	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BE	Belgium	GR	Greece		Republic of Macedonia	TR	Turkey
BF	Burkina Faso	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BG	Bulgaria	IE	Ireland	MN	Mongolia	UA	Ukraine
BJ	Benin	IL	Israel	MR	Mauritania	UG	Uganda
BR	Brazil	IS	Iceland	MW	Malawi	US	United States of America
BY	Belarus	IT	Italy	MX	Mexico	UZ	Uzbekistan
CA	Canada	JP	Japan	NE	Niger	VN	Viet Nam
CF	Central African Republic	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CG	Congo	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
СН	Switzerland	KP	Democratic People's	NZ	New Zealand		
CI	Côte d'Ivoire	Kı	Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany		Sri Lanka	SE	Sweden		
DK	Denmark	LK LR	Liberia	SG	Singapore		
EE	Estonia	LK	Ljucija	30	26-b		

Biodegradable Composite Material for Tissue Repair 1 2 The present invention relates to a composite material 3 which is especially useful in bone repair. 4 5 Most commonly defects to bone arise from injury, but 6 may also be due to congenital abnormalities, to 7 acquired deformity or to ablation of tumours. Without 8 adequate repair, bone defects can significantly affect 9 function of the associated limb, and frequently the 10 mobility of the patient is impaired. Where the bone 11 defect is present in the skull, there may be cosmetic 12 considerations and without adequate repair the 13 appearance of the patient may be adversely affected. 14 15 Repair and reconstruction of defective bone currently 16 involves either the use of auto-graft tissue (ie where 17 bone is removed from another part of the patient's body 18 and used for repair) or the use of bio-compatible 19 materials. Allograft bone transplants (ie using 20 donated bone material) are still the main source of 21 material for bone repair, despite the risk of disease 22 transmission, notably HIV or CJD, due to contaminated 23 sources. Both of the current approaches also suffer 24 other disadvantages: the need to obtain bone from the 25

patient for use in the auto-graft requires further 1 invasive procedure(s) and a second wound site in the 2 patient; and the bio-compatible materials currently 3 available are not suitable for all types of bone repair 4 and are particularly inadequate for repairing defects of the skull. 6 7 The present invention provides a biodegradable 8 composite material suitable for implantation in a 9 patient's body, said composite material comprising 10 water-soluble glass and a biodegradable polymer. 11 12 The water-soluble glass material may be in the form of 13 fibres, particles or mixtures thereof. As used herein 14 the term "glass fibres" refers to glass in both wool 15 The length of the fibres is and mono-filament form. 16 not critical and would normally be chosen to suit the 17 size of composite required. 18 19 Examples of suitable water-soluble glass fibres include 20 the fibres described in WO-A-98/54104, WO-A-99/62834 21 and WO-A-99/62835 (all in the name of Giltech Limited), 22 the content of each of these publications being 23 incorporated herein by reference. 24 25 The biodegradable polymer may be any suitable bio-26 compatible polymer or mixtures of such polymers. 27 Preferably the polymer exhibits some pliability or 28 Examples include (but are not limited to) plasticity. 29 polyvinyl alcohols, polysaccharides (for example 30 alginates and chitosan), polyglycolic acid, polylactic 31 acid, polyglycolactide, polyhydroxybutyrate, 32 polyhydroxyvaleriate, polycaprolactones (for example 33 poly ϵ -caprolactone), polycaprolactam and starches 34 (especially "thermoplastic" starches such as 35 hydroxypropylated starches, or potato, maize or rice 36

3

starch treated by high pressure and humidity). Co-1 polymers of these polymers may also be used (for 2 example polyglycolide (or polyglycolic acid)/ 3 polycaprolactone co-polymer or a polyglycolic 4 acid/polycaprolactam co-polymer). 5 6 A preferred biodegradable polymer is poly(ϵ -7 caprolactone), or any other slowly degrading polymer 8 material. 9 10 In one embodiment, the water-soluble glass material 11 will degrade more slowly (and usually at a 12 significantly slower rate) than the biodegradable 13 Alternatively, the biodegradable polymer will 14 degrade more slowly than the water-soluble glass 15 material. 16 17 Advantageously the glass material, in addition to 18 contributing to the strength of the composite material, 19 will provide a suitable environment for initiation of 20 bone repair. Desirably therefore osteoblasts are able 21 to penetrate the biodegradable polymer in order to 22 attach to the glass material and commence bone 23 formation. Generally the size of the glass material 24 will be selected to degrade in a time-scale comparable 25 to bone repair. 26 27 The polymer provides a sponge-like environment around 28 the water-soluble glass, and becomes wetted by body 29 fluids when the composite material is placed in the 30 Where water-soluble glass particles or fibres 31 are present in the composite, slight dissolution of 32 polymer occurs around the sites where the glass is 33 present and may cause a general loosening of the 34 The degree of loosening may be beneficial composite. 35 in some embodiments since the areas created are 36

PCT/GB00/00475 WO 00/47245

available for tissue ingrowth. Loss of mechanical 1 strength in the composite material may be countered by 2 including randomly orientated fibres and/or the release 3 of zinc ions from the glass, which would promote cross-4 linking and repolymerisation of the polymer (especially 5 poly ϵ -caprolactone) around the glass. 6

7 8

A further advantage of the composite described is that it is mouldable, and it may be contoured to fit the implant site closely.

10 11

9

The composite material may comprise a matrix of water-12 soluble glass material, the matrix being impregnated 13 with the biodegradable polymer. Optionally the glass 14 material (fibres and/or particles) is arranged to 15 provide adequate strength in the load-bearing 16 dimensions of the composite. 17

18

In a further aspect the present invention provides a 19 method of repairing an area of defective tissue (for 20 example nerve or bone) in a patient, said method 21 comprising implanting a composite material as described 22 above into said patient in sufficient quantity to cover 23 Optionally said composite and/or fill said area. 24 material is attached to healthy tissue using 25 conventional (preferably biodegradable) means. 26 may be of sutures and biodegradable glue in this 27 respect. 28

29

31

32

The biodegradable composite of the present invention 30 may be used to form pins, plates, nuts or bolts to hold shattered bone pieces together, or may be formed into flexible sheet form to wrap around a defective tissue.

33 34

In a further aspect, the present invention provides a 35 method of producing a composite material suitable for 36

PCT/GB00/00475

1	tissue repair, said method comprising:
2	
3	a) providing water-soluble glass fibres and/or
4	glass particles;
5	b) optionally arranging said fibres and/or
6	particles into a pre-selected order;
7	c) covering said fibres and/or particles with a
8	biodegradable polymer and if required allowing
9	said polymer to cure.
10	
11	In one embodiment the composite material may be formed
12	using liquid moulding techniques. For example the
13	required array of glass fibres and/or particles may be
14	positioned in a closed mould cavity into which the
15	polymer is then introduced. A rigid composite material
16	is formed once the polymer has cured. Optionally
17	introduction of the polymer into the mould may be
18	vacuum assisted.
19	
20	Where poly(ϵ -caprolactone) is used as the polymer,
21	conducting the polymerisation reaction within the mould
22	cavity itself may be desirable since introduction of
23	this polymer into the mould is difficult due to the
24	high viscosity of poly(ϵ -caprolactone). A ring-opening
25 .	polymerisation of caprolactone using 1,4-butanediol
26	catalyzed with diethylzinc may be suitable for such in
27	situ polymerisation.
28	the second of th
29	Alternatively, a suitable composite material may be
30	produced by forming glass fibre into a glass fibre
31	fabric which can then be simply dipped into the plastic
32	polymer. Alternatively, the polymer may be sprayed
33	onto the fibre. In addition to the techniques of
34	thermoforming and weaving, the glass fibres could also
35	be spun into a yarn, the fibres or yarn being
36	optionally knitted, braided or crocheted. Likewise

1	where glass wool is used, the wool may be shaped as
2	required and either dipped into the plastic polymer or
3	placed into a closed mould cavity for liquid moulding
4	as described above.
5	
6	In a further embodiment glass particles are used
7	together with short lengths of glass fibres.
8	
9	In a yet further aspect, the present invention provides
10	the use of a composite material as described above for
11	repairing damaged or defective tissue (especially bone
12	or nerve tissue) in a body.
13	
14	Desirably the composite material is sterilised prior to
15	implantation in the body, for example by irradiation.
16	
17	Phosphorous pentoxide (P_2O_5) is preferably used as the
18	glass former.
19	
20	Generally the mole percentage of phosphorous pentoxide
21	in the glass composition is less than 85%, preferably
22	less than 60% and especially between 30-60%.
23	
24	Alkali metals, alkaline earth metals and lanthanoid
25	oxides or carbonates are preferably used as glass
26	modifiers.
27	
28	Generally, the mole percentage of alkali metals,
29	alkaline earth metals and lanthanoid oxides or
30	carbonates is less than 60%, preferably between 40-60%.
31	
32	Boron containing compounds (eg B_2O_3) are preferably used
33	as glass additives.
34	
35	Generally, the mole percentage of boron containing
36	compounds is less than 15% or less, preferably less

7

than 10%, and usually around 5% or less. 1 2 Other compounds may also be added to the glass to 3 modify its properties, for example SiO2, Al2O3, SO3 or 4 transition metal compounds (eg. first row transition 5 metal compounds). Generally, the glass will release 6 ionic species upon dissolution, the exact ionic species 7 released depending upon the compounds added to the 8 glass. Glasses which release aluminium ions, sulphate 9 ions or fluorine ions may be desirable in some 10 circumstances. 11 12 Typically the soluble glasses used in this invention 13 comprise phosphorus pentoxide (P2O5) as the principal 14 glass-former, together with any one or more 15 glass-modifying non-toxic materials such as sodium 16 oxide (Na_2O), potassium oxide (K_2O), magnesium oxide 17 (MgO), zinc oxide (ZnO) and calcium oxide (CaO). 18 rate at which the glass dissolves in fluids is 19 determined by the glass composition, generally by the 20 ratio of glass-modifier to glass-former and by the 21 relative proportions of the glass-modifiers in the 22 By suitable adjustment of the glass 23 composition, the dissolution rates in water at 38°C 24 ranging from substantially zero to 25mg/cm²/hour or more 25 can be designed. However, the most desirable 26 dissolution rate R of the glass is between 0.01 and 27 2.0mg/cm²/hour. 28 29 The water-soluble glass is preferably a phosphate 30 glass, and may comprise a source of silver ions 31 which may advantageously be introduced during 32 manufacture as silver orthophosphate (Ag,PO4). 33 metals may alternatively or additionally be present and 34 mention may be made of Cu, Mg, Zn, Ce, Mn, Bi, Se, Cs. 35 Preferred metals include Ag, Cu, Zn and Mg. The glass 36

8

preferably enables controlled release of metal and 1 other constituents in the glass and the content of 2 these additives can vary in accordance with conditions 3 of use and desired rates of release, the content of 4 metal generally being up to 5 mole %. While we are 5 following convention in describing the composition of 6 the glass in terms of the mole % of oxides, of halides 7 and of sulphate ions, this is not intended to imply 8 that such chemical species are present in the glass nor 9 that they are used for the batch for the preparation of 10 the glass. 11

12

The optimum rate of release of metal ions into an 13 aqueous environment may be selected by circumstances 14 and particularly by the specific function of the 15 The invention provides a means of released metal. 16 delivering metal ions to an aqueous medium at a rate 17 which will maintain a concentration of metal ions in 18 said aqueous medium of not less than 0.01 parts per 19 million and not greater than 10 parts per million. In 20 some cases, the required rate of release may be such 21 that all of the metal added to the system is released. 22 in a short period of hours or days and in other 23 applications it may be that the total metal be released 24 slowly at a substantially uniform rate over a period 25 extending to months or even years. In particular cases 26 there may be additional requirements, for example it. 27 may be desirable that no residue remains after the 28 source of the metal ions is exhausted or, in other 29 cases, where the metal is made available it will be 30 desirable that any materials, other than the metal 31 itself, which are simultaneously released should be 32 physiologically harmless. In yet other cases, it may 33 be necessary to ensure that the pH of the resulting 34 solution does not fall outside defined limits. 35

9

Generally, the mole percentage of these additives in 1 the glass is less than 25%, preferably less than 10%. 2 .3 Embodiments of the invention will be described with 4 reference to the following non-limiting examples. 5 6 Example 1 7 8 Method of forming a glass fibre 9 10 The glass-forming composition is initially heated to a 11 melting temperature of 500°-1200°C, preferably 750°-12 The temperature is then slowly lowered to the 13 working temperature at which fibre formation occurs. 14 15 Generally, the working temperature of the glass will be 16 at least 200°C lower than the temperature at which the 17 glass is initially heated. Suitable working 18 temperatures may fall within the following ranges 400°-19 500°C, 500°-900°C (preferably 550°-700°C, more 20 preferably 550°-650°C, especially 600°-650°C) and 800-21 The working temperature selected will depend 22 upon the glass composition, but an approximate 23 indication of a suitable working temperature can be 24 established as hereinafter described. Depending upon 25 the glass composition used, the working temperature may 26 be a range of suitable temperatures. The range of 27 working temperatures may be narrow, for example of only 28 10°C, so that fibre formation may occur only between 29 the temperature of N°C to (N+10)°C. Other glass 30 compositions may have a wider temperature range for the 31 working temperature in which glass formation is 32 possible. 33 34 Alternatively, the working temperature of the glass may 35 be defined as 50-300°C above the Tg of the glass. 36

PCT/GB00/00475 WO 00/47245

10

In order to obtain an approximate indication of the 1 working temperature for any particular glass composition, the glass composition should be slowly 3 heated to its melting point. As soon as the glass is molten, frequent attempts to pull the composition 5 upwardly to form a fibre should be made, with the temperature of the composition being very gradually 7 increased between attempts. The temperature range of 8 the composition during which fibre formation is 9 possible should be noted and used as a preliminary 10 working temperature in the process of the invention. 11 12 It will be clear to those skilled in the art that the 13 pulling speed at which the fibre is drawn off can 14 affect the choice of working temperature and the 15 diameter of the fibre required. Where a fibre of 16 relatively large diameter is required, the fibre tends 1.7 to be pulled more slowly and the working temperature 18 may need to be decreased slightly. Where a fibre of 19 relatively small diameter is required (eg a glass 20 wool), the fibres may be drawn at the much higher 21 pulling speed and the working temperature may need to 22 be increased (thus lowering the viscosity of the 23 composition to accommodate the increased pulling 24 Selection of the exact working temperature in 25 respect of any particular fibre size and composition 26 will be a simple matter of routine evaluation of 27 optimal process conditions. 28 29 With reference to the "working temperature" of the 30 glass, the skilled person will appreciate that the 31 furnace temperature may differ considerably from the 32 temperature of the glass itself and indeed there may be 33 a significant temperature gradient in the glass. 34 Ideally the "working temperature" will be the 35 temperature of the glass as fibre formation (ie.

11

pulling) takes place. In many compositions however, it 1 may not be practical to measure the temperature at the 2 surface of the glass where pulling occurs by insertion 3 of a temperature probe as the introduction of the probe 4 may precipitate crystallisation of the glass. 5 alternative is to place a temperature probe into the 6 bushing and to monitor the bushing temperature which 7 will be a good indicator of the glass temperature at 8 Alternatively an Infra the moment of fibre formation. 9 Red pyrometer may be focused onto the appropriate area 10 of the glass and used to monitor the temperature. 11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

The glass to be formed into fibres will generally be heated until molten, optionally clarified, and then cooled slowly and controllably until the appropriate working temperature is reached and fibre formation can The initial heating of the glass above its commence. melting point and the subsequent fibre formation may be carried out in a single vessel or, alternatively, the molten glass may be transferred to a vessel designed specifically for fibre formation. One way of holding the molten glass in a vessel having a bushing within its lower surface until the temperature drops to the required working temperature is to coat or fill the holes of the bushing with a material that gradually melts over the period of time taken for the glass to reach the temperature required.

272829

30

31

32

33

34

35

36

The most important aspect of the method is the manner in which the working temperature is reached. We have found that the molten glass, which may preferably be heated significantly above its melting point, should be allowed to cool in a highly controlled manner, the temperature being only gradually reduced until the working temperature is reached. A stirrer may be present to ensure that the temperature of the whole of

12

the molten glass is kept as uniform as possible.

2

The glass is cooled to a temperature at which the glass 3 will not crystallise for at least the period of time 4 needed to convert the melt to fibre. This temperature 5 is termed herein as a "holding temperature". of cooling from this holding temperature is determined 7 by the rate at which the melt is consumed at the 8 bushing and the difference in temperature between the 9 bushing temperature (the working temperature) and the 10 melt holding temperature. 11

12

Due to low viscosity and narrow temperature band for many of these compositions, control of the balance between melt temperature, bushing temperature and glass throughput rate is critical.

17

Examples 2 to 16 detail suitable compositions which can be formed into fibres using the method of Example 1. Alternatively, these glasses can be cast in a conventional way and used to form particles, powder or granules.

23

24 Example 2

25		Component	Mole %
26	Glass Composition		
27		Na ₂ O	31.05
28		CaO	16.00
29		Ag₂O	3.88
30		P_2O_5	46.08
31		Na_2PO_3F	0.97
32		2Al ₂ O ₃ .B ₂ O ₃	2.00

33

100 grams of the sample was heated to 900°C before being cooled and pulled at 650°C, at 25 km/hr. Overall the fibre was good; one sample was 10 km in length and

PCT/GB00/00475

	11 grams in weight, although there was some
2	crystallisation at the pulling temperature.

4	Example 3		
5		Component	Mole %
6	Glass Composition		
7		Na ₂ O	29.51
8		CaO	15.21
9		Ag₂O	3.68
10		P ₂ O ₅	43.80
11		$2Al_2O_3.B_2O_3$	1.90
		Na ₂ PO ₃ F	1.90
12		$Na_2B_4O_7.10H_2O$	1.00
13		Na ₂ PO ₄	3.00
14		Na ₂ FO ₄	2.00

74 grams of the sample was heated to 1000°C before being cooled and pulled at 635°C at 25 km/hr. The fibre produced was ultrafine; one sample was 18 km in length and 59 grams in weight. The sample was sprayed with WD40 to prevent water absorption and to aid lubricity. There was some debris at the bottom of the crucible, but this was found to be just iron deposits from the brushing rod.

25	Example 4		
26	.•	Component	Mole %
27	Glass Composition		
28		Na ₂ O	34.20
29		CaO	16.15
30		P_2O_5	44.65
31		Na ₂ SO ₄	5.00
Σ Γ		• •	•

200 grams of the sample was heated to 1050°C before being cooled and pulled at 635°C at 25 km/hr. The fibre was good although there was some crystallisation at the pulling temperature.

1	Example 5		
2		Component	Mole %
3	Glass Composition		
4		Na ₂ O	32.40
5		CaO	15.30
6	•	P_2O_5	42.30
7		$2Al_2O_3.B_2O_3$	3.00
8		Na_2PO_3F	1.00
9		Na ₂ SO ₄	6.00
-			

117 grams of the sample was heated to 950°C before being cooled and pulled at 635°C, at 40 km/hr. The fibre produced was good and there were no crystallisation problems even though the surface temperature of the fibre dropped to 510°C in the pulling process.

Example 6

19		Component	Mole %
20	Glass Composition		
21		Na ₂ O	31.71
22		CaO	14.73
23		P_2O_5	36.33
24		B_2O_3	4.78
25		SO ₃	9.40
26		Na_2PO_3F	3.00

99 grams of the sample was heated to 800°C before being cooled to 650°C and pulled at 40 km/hr. The fibre produced was very fine but difficult to pull and quite fragile at speed.

PCT/GB00/00475 WO 00/47245

1	Example 7		
2		Component	Mole %
3	Glass Composition		
4		Na₂O	30.77
5		CaO	14.28
		P_2O_5	35.28
6	•		4.64
7		B_2O_3	
8		SO₃	9.12
9		FePO ₄	2.41
		Na_2PO_3F	0.20
10		- -	0.00
11		Na ₂ PO ₃ F	0.20
		MnHPO ₄	2.06
12			

13 14

15

16

17

18

200 grams of the sample was heated to 850°C before being cooled to 545°C and pulled at 40 km/hr. fibre produced was strong and thin; there was not a problem of crystallisation, in fact the glass can be stored at 550°C for 72 hours without the onset of crystallisation.

19 20 21

Example 8

Below is an example of a wool formulation and running 22 conditions to illustrate the differences with the 23 monofilament examples given above. 24

25 26

A typical wool formulation is

27

28	Na ₂ O	26.31
29	CaO	17.78
30	P_2O_5	47.04
31	B_2O_3	5.94
32	MnO	1.55
33	Fe ₂ O ₃	0.97
34	NaF	0.41

- Solution rate, non annealed = 0.0278 mg.cm⁻²hr⁻¹ 36
- Melted and refined at 1000°C. 37
- Cooled and held at 725°C. 38
- Bushing temperature maintained at 365°C. 39

Thick fibres approx 1.2mm diameter drawn through pinch 1

- rollers at 2.5 $\rm M.mm^{-1}$ from a bushing with 6 x 6.5mm 2
- diameter holes. Fibres jet attenuated to produce a 3
- fine wool 5 -15 μm diameter. The wool was sprayed with 4
- silicone oil finish during the attenuation process and 5
- collected on a stainless steel mesh conveyor. 6
- Typically, attenuated wools will have diameters of 5 to 7
- Monofilament fibres will mostly be 20 to $50\,\mu m$ 8
- diameter. 9

10

```
Example 9
11
```

31.19 mole % Na₂O 12 mole % 9.63 13 K_2O

2.9 mole % Ag₂O 14 mole %

2.74 B_2O_3 15 0.66 mole % 2NaF 16

52.88 mole % $P_{2}O_{5}$ 17

Furnace at 710°C - 800°C. 18

- Bushing at 450°C 460°C. 19
- 4.5mm bushing holes. 20
- 50km per hour pull rate. 21
- Good fibres. 22
- Solution rate = 1.68 not annealed 2.28 annealed. 23

24

30

Example 10 25

32 mole % Na_2O 26 10 mole % K_2O 27 mole % 28 Ag₂O 55 mole % P_2O_5

29

Furnace at 850°C. 31

- Bushing at 530°C. 32
- 5mm bushing holes. 33
- 55kmph. 34
- Good strong fibres. 35

36

37

38

17 Example 11 1 32 mole % Na_2O 2 10 mole % K₂O 3 mole %) - added as an anti-microbial (MgO . 4 5 mole % B_2O_3 5 3 mole % Ag₂O 6 46 mole % 7 P_2O_5 8 Furnace temperature 650°C - 730°C. 9 Bushing temperature 410°C - 420°C. 10 Bushing 5.5mm diameter. 11 Speed up to 100kmph. 12 Solution rate 0.7 annealed 1.0 non annealed (mg.cm⁻³.hr⁻¹). 13 Very good strong reliable fibre. Very stable. 14 15 Example 12 16 36.68 mole % Na₂O 17 8.63 mole % K_2O 18 45.09 mole % 19 $P_{2}O_{5}$ 5.29 mole % B_2O_3 20 2.59 mole % Ag_2O 21 1.73 mole % to attenuate solution rate! (CaO 22 23 Furnace temperature 550°C. 24 Bushing 62 \times 5.0mm holes. 25 Bushing temperature 400°C. 26 Speed 80kmph. 27 Very good fibres. 28 Solution rate 3.11 annealed, 3.8 non annealed (mg.cm⁻².hr⁻¹). 29 30 The fibres show excellent tensile strength, flexibility 31 and shock resistance. 32 33 The fibres are especially suitable for industrial and 34 plastics reinforcement controlled release (anti-35 microbial, anti-corrosion etc) and rapidly 36 biodegradable applications.

38 39

Anti-microbial.

```
Example 13
 1
                       30 mole %
      CaO
 2
                       20 mole %
      MgO
 3
                        50 mole %
 4
      P_{2}O_{5}
 5
      Furnace at 1050°C.
 6
      Bushing 5.5mm holes.
 7
      Bushing temperature 700°C - 720°C.
 8
      Speed up to 80kmph.
 9
      Solution rate TBA.
10
      Very strong fibre.
11
12
      Example 14
13
                            mole %) Trace to alter dissolution rate
      (K_2O)
                       5
14
                            mole %
                       25
      CaO
15
                            mole %
                       20
      Mg<sub>2</sub>O
16
                            mole %
                        50
17
      P_{2}O_{5}
18
      Furnace 1000°C.
19
      Bushing 5.5mm.
20
      Bushing temperature 560°C - 620°C.
21
      Speed up to 70kmph.
22
      Solution rate TBA.
23
      Very strong fibre.
24
      Anti-microbial.
25
26
      Example 15
27
                       28.5
                              mole %
      CaO
28
                              mole %
                       18.5
      MgO
29
                              mole %
                       3
      Ag<sub>2</sub>O
30
                              mole %
                       50
      P_2O_5
31
32
      Furnace temperature 1050°C - 1150°C.
33
      Bushing 4 x 5.5mm.
34
      Bushing temperature 700°C.
35
      Speed 50kmph.
36
      Solution rate TBA.
37
      Very good, strong fibre.
38
```

Example 16 1 30 mole % CaO 2 20 mole % MqO 3 50 mole % P_2O_5 4 5 As Example 15 (without silver) 6 7 The fibres show excellent tensile strength, flexibility 8 These fibres are suitable for and shock resistance. 9 applications requiring slower release and greater 10 tensile strength plus biodegradability. The fibres are 11 suitable for orthopaedic implants and tissue 12 engineering applications. 13 14 Example 17 15 Producing a composite comprising soluble glass powder 16 or granules. 17 18 Glass powder or granules can be added to the polymer to 19 reinforce, stiffen or bulk the composite. The glass 20 (for example based on the glasses of any of Examples 1 21 to 16) can be used to release, for example, 22 antimicrobials or trace elements. The glass, whose 23 solution rate can be varied as required, reduces the 24 volume of polymer to be degraded when used as a bulking 25 agent. 26 27 The powder or granules/polymer composition can be made 28 in various ways, as follows: 29 30 Mixing the glass with solvent dissolved polymer, 1. 31 e.g. polycaprolactone can be dissolved in 32 chloroform. Glass is added to the liquid and 33 The solvent is evaporated to leave the 34 composite. 35 36 The glass can be mixed into melted polymer. 37 2.

The glass can be added to polymer masterbatch

38

39

З.

which can then be used in extrusion or coextrusion processes.

3 · 4

Example 18

Producing a composite comprising soluble glass fibre.

5 6 7

8

9

The addition of biodegradable glass fibre (as described in any of Examples 1 to 16) for reinforcement, bulking or controlled release in the polymer may be achieved by various methods, as follows:

10 11

1. Fibre can be passed through a bath of polymer
dissolved in solvent. The polymer solution can
also be applied by passing the fibre over a
rotating or counter-rotating transfer roller.

16

2. Solvent dissolved polymer can be sprayed directly onto fibre as it is collected onto a drum or atomised into the jet attenuation venturi to produce coated wool.

21

22 3. Continuous fibre can be fed through a bath of 23 melted polymer.

24

25 4. Fibre can be mixed into melted polymer or knitted 26 or pre-formed into shapes to be layered into 27 melted polymer. It may be possible to make sheets 28 of polymer/fibre "sandwich" which can be thermally 29 formed in a press.

21 CLAIMS 1 2 A biodegradable composite material suitable for 3 1. implantation into a patient's body, said composite 4 material comprising water-soluble glass and a 5 biodegradable polymer. 6 7 The composite material as claimed in Claim 1, 2. 8 wherein said biodegradable polymer is a polyvinyl 9 alcohol, polysaccharide, polyglycolic acid, 10 polylactic acid, polyhydroxybutyrate, 11 polyhydroxyvaleriate, polycaprolactone, 12 polycaprolactam or a starch. 13 14 The composite material as claimed in Claim 2 3. 15 wherein said biodegradable polymer is poly ϵ -16 caprolactone. 17 18 The composite material as claimed in any one of 4. 19 Claims 1 to 3 wherein said water-soluble glass is 20 in the form of glass fibres and/or particles. 21 22 The composite material as claimed in any one of 5. 23 Claims 1 to 4 which comprises a matrix of water-24 soluble glass fibres and/or particles impregnated 25 with said biodegradable polymer. 26 27 A method of repairing an area of defective tissue 6. 28 in a patient, said method comprising inserting the 29 composite material as claimed in any one of Claims 30 1 to 5 into said patient in a quantity sufficient 31 to cover and/or fill said area. 32 33 The method as claimed in Claim 6 wherein said 7. 34 tissue is nerve or bone. 35 36

The method as claimed in either one of Claims 6 8. 37 and 7 wherein said composite material is attached 38 to healthy tissue by suture and/or by 39

PCT/GB00/00475

1		biodegradable adhesive.
2		
3	9.	A method of producing a composite material
4		suitable for tissue repair, said method
5		comprising:
6		
7		 a) providing water-soluble glass fibres and/or
8		glass particles;
9		b) optionally arranging said fibres and/or
10		particles into a pre-selected order;
11		c) covering said fibres and/or particles with a
12		biodegradable polymer and if required allowing
13		said polymer to cure.
14		
15	10.	The method as claimed in Claim 9 wherein said
16		biodegradable polymer is poly ϵ -caprolactone and
17		wherein polymerisation occurs within the mould.

INTERNATIONAL SEARCH REPORT

intern hal Application No PCT/GB 00/00475

CLASSIFICATION OF SUBJECT MATTER PC 7 A61L27/58 A61L A CLAS A61L31/14 A61L31/12 A61L27/42 A61L27/46 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) A61L IPC 7 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the International search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Citation of document, with indication, where appropriate, of the relevant passages 1,2,6-8 DE 195 08 647 A (BIOVISION GMBH) X 11 January 1996 (1996-01-11) 1-3,6,7EP 0 146 398 A (SOUTHERN RES INST) X 26 June 1985 (1985-06-26) page 4; claims 1,2,6-8 DATABASE WPI X Section Ch, Week 199904 Derwent Publications Ltd., London, GB; Class A14, AN 1999-040635 XP002138589 & JP 10 298108 A (DAINIPPON INK & CHEM INC), 10 November 1998 (1998-11-10) abstract -/--Patent family members are listed in annex. X Further documents are listed in the continuation of box C. X Special categories of cited documents : To later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the "A" document defining the general state of the art which is not considered to be of particular relevance invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "E" earlier document but published on or after the International filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docu-*O* document referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family Date of mailing of the international search report Date of the actual completion of the international search 07/06/2000 24 May 2000 Authorized officer

1

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijawijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni, Fax: (+31-70) 340-3016

ESPINOSA, M

INTERNATIONAL SEARCH REPORT

Interr hal Application No PCT/GB 00/00475

		PC1/4B 00/004/5		
C.(Continue	ation) DOCUMENTS CONSIDERED TO BE RELEVANT			
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X ·	GB 2 169 914 A (MITSUBISHI MINING & CEMENT CO) 23 July 1986 (1986-07-23) claims; examples	1,2,4-7		
X	WO 97 33632 A (GILTECH LTD ;GILCHRIST EILIDH (GB); GILCHRIST THOMAS (GB)) 18 September 1997 (1997-09-18) claims; examples 1-3	1,2		
Ρ,Χ	CORDEN T J ET AL: "Initial development into a novel technique for manufacturing a long fibre thermoplastic bioabsorbable composite: in-situ polymerisation of poly-epsilon-caprolactone" COMPOSITES PART A: APPLIED SCIENCE AND MANUFACTURING, NL, ELSEVIER SCIENCE PUBLISHERS B.V., AMSTERDAM, vol. 30, no. 6, June 1999 (1999-06), pages 737-746, XP004164010 ISSN: 1359-835X page 738 page 745	1-10		
P,X	WO 99 11296 A (BIONX IMPLANTS OY) 11 March 1999 (1999-03-11) claims; examples	1-10		
A	US 4 604 097 A (KUMAR BINOD ET AL) 5 August 1986 (1986-08-05) claims	1-10		
A	WO 98 44965 A (HEALY DAVID MICHAEL; GILTECH LTD (GB)) 15 October 1998 (1998–10–15) claims	1-10		

INTERNATIONAL SEARCH REPORT

unformation on patent family members

Interr hal Application No PCT/GB 00/00475

Patent document cited in search report		Publication date	Patent family member(s)			Publication date
DE 19508647	A	11-01-1996	NONE			
EP 0146398	Α	26-06-1985	US	46557	77 A	07-04-1987
EL 0140330	^	20 00 2000	CA	12619	91 A	26 - 09-198 9
			JP	601538	68 A	13-08-1985
JP 10298108	A	10-11-1998	NONE			
an 0160014	Α	23-07-1986	JP	14717	47 C	14-12-1988
GB 2169914	n	23 07 1300	JP	611356	71 A	23-06-1986
			JP	630191		21-04-1988
			CH		81 A	15-07-1988
			DE	35425		05-06-1986
			NL	85033		01-07-1986
			ÜS	50133		07-05-1991
		18-09-1997	AU	20329	97 A	01-10-1997
WO 9733632	A	10-03-1337	CA	22479		18-09-1997
			EP	0888		07-01-1999
WO 9911296	A	11-03-1999	AU	96228	398 A	22-03-1999
UC 4604007	Α	05-08-1986	AU	5518	386 A	10-09-1980
US 4604097	^	00 00 100	EP	0211	942 A	04-03-1987
			ĴΡ	7005		25-01-199!
			ĴΡ	62501		30-07-1987
			WO	8604		28-08-198
		15-10-1998	AU	6928	598 A	30-10-199
WO 9844965	Α	19-10-1990	EP		562 A	26-01-200

THIS PAGE BLANK (USPTO)